Literature DB >> 10404058

Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases.

M Dueck1, S Riedl, U Hinz, A Tandara, P Möller, C Herfarth, A Faissner.   

Abstract

The glycoprotein tenascin-C is up-regulated in inflammatory and neoplastic diseases. Most available data on tissue tenascin-C content do not distinguish its various isoforms. We have quantified tissue tenascin-C signals in colorectal mucosa, ulcerative colitis, colorectal carcinomas and liver metastases using 5 monoclonal antibodies (MAbs) with different binding sites. Tenascin-C of tissue extracts was analyzed by a standardized Western blot technique and densitometry. As a reference MAb, K8 displayed tenascin-C tissue concentrations of 4.1 +/- 2.3 microgram/mg total protein in normal mucosa, 13.8 +/- 4.7 microgram/mg in ulcerative colitis, 28.8 +/- 14.5 microgram/mg in colorectal carcinomas and 25.6 +/- 8.9 microgram/mg in liver metastases. The optical density values per microgram protein tissue extract of the 5 MAbs reflect the levels of the corresponding tenascin-C epitopes. Various signal intensities indicate a distinct diagnostic usefulness of the MAbs in detecting colorectal carcinomas. The binding characteristics of MAb J1/tn2 point to an under-representation of the TNfnD domain in metastasizing colorectal carcinomas, while MAb 19H12 showed an increased binding rate on the TNfnA1,2,4 region. Our comparative study of tenascin-C in inflammatory and neoplastic diseases of the colon mucosa substantiates the occurrence of large differences in the diagnostic value of tenascin-C MAbs. The detected alterations of tenascin-C in metastasizing colorectal carcinomas might indicate a prognostic value of specific tenascin-C isoforms. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404058     DOI: 10.1002/(sici)1097-0215(19990812)82:4<477::aid-ijc2>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer.

Authors:  Akihiko Takeda; Yoshihide Otani; Hiroyoshi Iseki; Hideki Takeuchi; Kimiyasu Aikawa; Satoru Tabuchi; Nozomi Shinozuka; Toshiaki Saeki; Yasushi Okazaki; Isamu Koyama
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

2.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

Review 3.  Role of tenascins in the ECM of gliomas.

Authors:  Nicole Brösicke; Andreas Faissner
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 4.  Revisiting the Tenascins: Exploitable as Cancer Targets?

Authors:  Richard P Tucker; Martin Degen
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

5.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

6.  Prognostic value of β1 integrin expression in colorectal liver metastases.

Authors:  Nikolaos Vassos; Tilman Rau; Susanne Merkel; Fabian Feiersinger; Carol I Geppert; Michael Stürzl; Werner Hohenberger; Roland S Croner
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

7.  Involvement of large tenascin-C splice variants in breast cancer progression.

Authors:  Takatsugu Tsunoda; Hiroyasu Inada; Ilunga Kalembeyi; Kyoko Imanaka-Yoshida; Mirei Sakakibara; Ray Okada; Koji Katsuta; Teruyo Sakakura; Yuichi Majima; Toshimichi Yoshida
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

Review 8.  Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.

Authors:  R K Boyapati; A G Rossi; J Satsangi; G-T Ho
Journal:  Mucosal Immunol       Date:  2016-03-02       Impact factor: 7.313

9.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

10.  A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo.

Authors:  Alberto Dal Corso; Rémy Gébleux; Patrizia Murer; Alex Soltermann; Dario Neri
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.